Heat shock protein inhibitors for the treatment of fungal infections

Recent Patents on Anti-Infective Drug Discovery

Volumn 6, Issue 1, 2011, Pages 38-44

  Wirk, Baldeep ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

17 AAG; Efungumab; Fungal infections; Geldanamycin; Heat shock protein 90; Immunocompromised

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; EFUNGUMAB; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; PLACEBO; TANESPIMYCIN;

ANTIFUNGAL ACTIVITY; ARTICLE; BACKACHE; BLISTER; CHILL; COMBINATION CHEMOTHERAPY; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; FEVER; HUMAN; HYPERTENSION; HYPOTENSION; INVASIVE CANDIDIASIS; MONOCYTE; MONOTHERAPY; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; RASH; SEPTIC SHOCK; SIDE EFFECT; STRUCTURE ANALYSIS; TACHYCARDIA; TREATMENT OUTCOME;

ANIMALS; ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; FUNGI; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MODELS, MOLECULAR; MYCOSES; PATENTS AS TOPIC;

EID: 79551652182     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489111794407840     Document Type: Article

References (55)

1. Dimopoulous G, Karabinis A, Samonis G, Falagas ME. Candidemia in immunocompromised and immunocompetent critically ill patients: A prospective comparative study. Eur J Clin Microbiol Infect Dis 2007; 26: 377-84.
2. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006; 20: 485-506.
3. Pfaller MA, Dickema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.
4. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzes RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 307-17.
5. Kremery V, Barnes AJ. Non-albicans Candida sp. Causing fungaemia, pathogenicity and antifungal resistance. J Hosp Infect 2002; 50: 243-60.
6. Singh N, Paterson DL. Aspergillus infection in transplant recipients. Clin Microbiol Rev 2005; 18: 44-69.
7. Klepser ME. Antifungal resistance among Candida species. Pharmacotherapy 2001; 21: 5124-32.
8. Pappas PG, Kauffman CA, Andes D, Benjamin DF, Calandra TF, Edwards JE, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
9. Anderson JB. Evolution of antifungal drug resistance: Mechanisms and pathogen fitness. Nat Rev Microbiol 2005; 3: 547-56.
10. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 2002; 359: 1135-44.
11. Vartivarian S, Smith CB. Pathogenesis, host resistance and predisposing factors. In: Bodey GP, Ed. (Chap 1) Candidiasis. 2nd ed. New York (NY): Raven Press Ltd. 1993; 59-84.
12. Matthews R, Burnie J, Smith D, Clark I, Midgley J, Connolly M, et al. Candida and AIDS: Evidence for protective antibody. Lancet 1988; 101: 263-6.
13. Casadevall A. Antibody immunity and invasive fungal infections. Infect Immun 1995; 63: 4211-8.
14. Wandinger SK, Richter K, Buchner J. Hsp90 chaperone machinery. J Biol Chem 2008; 283: 18473-7.
15. Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: Drug resistance in diverse fungi. Science 2005; 309: 2185-9.
16. Soo EJL, Yip CWC, Lwin ZM, Kumar SD, Bay BH. Heat shock proteins as novel targets in cancer. In Vivo 2008; 22: 311-6.
17. Dutta R, Inouye M. GHKL, an emergent ATPase/kinase superfamily. Trends Biochem Sci 2000; 25: 24-8.
18. Messauoudi S, Peyrat JF, Brion JD, Alami M. Recent advances in Hsp90 inhibitors as antitumor agents. Anti-Cancer Agents Med Chem 2008; 8: 761-82.
19. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of Hsp90 confers tumor selectivity of Hsp90 inhibitors. Nature 2003; 25: 07-10.
20. Joly AL, Wettstein G, Mignot G, Ghiringhelli F, Garrido C. Dual role of heat shock proteins as regulators of apoptosis and innate immunity. J Innate Immun 2010 (Epub Ahead of Print).
21. Soti C, Racz A, Csernely P. A nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. J Biol Chem 2002; 277: 7066-75.
22. Stirling PC, Bakhoum F, Feigl AB, Leroux MR. Convergent evolution of clamp-like binding sites on diverse chaperones. Nat Struct Mol Biol 2006; 13: 865-70.
23. Meyer P, Prodromou C, Hu B, Vaughan C, Roe SM, Panaretou B, et al. Structural and functional analysis of the middle segment of Hsp90; implication for ATP hydrolysis and client protein and cochaperone interactions. Mol Cell 2003; 11: 647-58.
24. Kim, Y.J., Lee, G.I. Geldanamycin. KR9030785 (2008).
25. Licari, P.J., Leaf, T., Desai, R., Galazzo, J.L., Buchanan, G.O., Watt, S.W., Eberlin, A.R., Arslanian, R. New purified polymorph C or G of 17-allylamino-17-demethoxygeldanamycin. US7648976 (2010).
26. Zhang L, Boehm MF, Zegar S. Process for preparing 17-Allyl aminogeldanamycin (17-AAG) and other ansamycins. US7579462 B2 (2009).
27. Santi D, Mylers DC, Tian ZQ, Hutchinson CR, Johnson R, Zhou YQ, et al. Benzoquinone ansamycins. US6872715 (2005).
28. Ulm EH, Chen AX, Boehm MF. Ansamycin formulations and methods for producing and using same. US0014730 (2006).
29. Ross D, Siegel D, Relgan P, Guo W, Gustafson DL. Hsp inhibitors, methods of making and uses therof. US7608611 B2 (2009).
30. Qin HL, Panek JS. Total synthesis of the Hsp90 inhibitor geldanamycin. Org Lett 2008; 10: 2477-9.
31. Usmani SZ, Bona R, Li Z. 17-AAG for Hsp90 inhibition in cancerfrom bench to bedside. Curr Mol Med 2009; 9: 654-64.
32. Whitesell L, Lindquist SL. Hsp90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761-72.
33. Borkovich KA, Farrelly FW, Finkelstein DB, Taulien J, Lindquist S. Hsp82 is an essential protein that is required at higher temperatures. Mol Cell Biol 1989; 9: 3919-30.
34. Cowen LE. Hsp90 orchestrates stress response signaling governing fungal drug resistance. PLoS Pathol 2009; 5(8): e 1000471.
35. Geller R, Vignuzzi M, Andino R, Frydman J. Evolutionary constraints on chaperone mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev 2007; 21: 195-205.
36. Srivastava P. Roles of heat shock protein in innate and adaptive immunity. Nat Rev Immunol 2002; 2: 185-94
37. Matsumoto S, Tanaka E, Nemoto JK. Ono T, Takagi K, Imai J, et al. Interaction between the N terminal and middle regions is essential for the in vivo function of hsp90 molecular chaperone. J Biol Chem 2002; 239: 34959-66.
38. Brandt GE, Blagg BS. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases. Curr Top Med Chem 2009; 9: 1447-61.
39. Powers MV, Workman P. Inhibitors of the heat shock response: Biology and pharmacology. FEBS Lett 2007; 581: 3758-69.
40. Cowen LE, Singh SD, Kohler JR, Collins C, Zaas AK, Schell WA, et al. Harnessing Hsp90 function as a powerful broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci USA 2009; 106: 2818-23.
41. Burnie, J.P., Matthew, R.C. Efungumab. Treatment of fungal infection with polyene or beta glucan synthase inhibitor antifungals combined with Hsp90 inhbitors. EP0000071 (2009).
42. Burnie, J.P. Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with Hsp90 antibodies. US0180285 (2003).
43. Burnie, J.P., Matthews RC. Use of an inhibitor of an Hsp90 protein for the manufacture of a medicament for the treatment of prophylaxis of a condition involving raised levels of TNFalpha and/or IL-6. US0154478 (2007).
44. Matthews RC, Rigg G, Hodgetts S, Carter T, Chapman C, Gregory C, et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal Hsp90. Antimicrob Agents Chemother 2003; 47: 2208-16.
45. Hodgetts S, Nooney L, Al-Akeel R, Curry A, Awad S, Matthews R, et al. Efungumab and caspofungin: Pre-clinical data supporting synergy. J Antimicrob Chemother 2008; 61: 1132-9.
46. Matthews RC, Burnie JP. Recombinant antibodies: A natural partner in combinatorial antifungal therapy. Vaccine 2004; 22: 865-71.
47. Pachl J, Svoboda P, Jacobs F, Vanderwoude K, van der Hoven B, Spronik P, et al. A randomized, blinded, multicenter trial of lipid associated amphotericin B alone versus in combination with an antibody based inhibitor of combination with an antibody based inhibitor of heat shock protein 90 in patients with invasive candidias. Clin Infect Dis 2006; 42: 1404-13.
48. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone Hsp90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci 2007; 1113: 202-16.
49. Neckers L. Heat shock protein 90: The cancer chaperone. J Biosci 2007: 32: 517-30.
50. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DTdiaphorase expression and tumor cell sensitivity to 17-allylamino 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999; 91: 1940-9.
51. Davis JM, Rowley SD, Braine HG, Piantadosi S, Santos GW. Clinical toxicity of cryopreserved bone marrow graft infusion. Blood 1990; 75: 781-6.
52. Dye D, Watkins J. Suspected anaphylactic reaction to Cremophor EL. Br Med J 1980; 280: 1353.
53. Nooney L, Matthews RC, Burnie JP. Evaluation of Mycograb, amphoteric B, Caspfungin and fluconazole in combination against Cryptococcus neoformans by checkerboard and time kill methodologies. Diagn Microbiol Infect Dis 2005; 51: 19-29.
54. Kumar R, Musiyenko A, Barik S. Plasmodium flaciparum calcineurin and its association with heat shock protein 90: Mechanisms for the antimalarial activity of cyclosporin A and synergism with geldanamycin. Mol Biochem Parasitol 2005; 141: 29-37.
55. Ali MM, Roe SM, Vaughan CK, Meyer P, Panaretou B, Piper PW, et al. Crystal structure of an Hsp90-nucleotide-p23/SBA1 closed chaperone complex. Nature 2006: 440: 1013-7.